Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in relapsed/refractory AML and high-risk MDS
2013-001570-14Phase 2Terminated
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Roche. Primary endpoint: Overall response rate. Started Jul 2013; status: terminated.
02
Drugs
vismodegib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-001570-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001570-14.